/
ROIV
$35.71+$0.98 (+2.81%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$24.5B
719M shares
52-week range
$10.71 – $35.90
99% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.25%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$26.35
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $67.7M | $23.8M | $55.3M | $31.5M | $32.7M | $29.1M | $8.3M |
| Cost of revenue | $1.1M | $2.1M | $9.0M | $3.0M | $1.6M | $911.0K | $1.3M |
| Gross profit | $66.6M | $21.7M | $46.3M | $28.5M | $31.1M | $28.1M | $7.0M |
| Gross margin | 98.3% | 91.4% | 83.8% | 90.4% | 95.1% | 96.9% | 84.4% |
| R&D | $263.2M | $236.6M | $483.0M | $454.1M | $439.9M | $550.4M | $681.8M |
| Operating income | −$532.4M | −$1.07B | −$1.21B | −$809.0M | −$824.9M | −$1.11B | −$1.29B |
| EBITDA | −$553.3M | −$895.7M | −$910.8M | −$838.2M | $4.62B | −$667.5M | −$261.2M |
| Net income | $1.20B | −$809.2M | −$845.3M | −$1.01B | $4.35B | −$172.0M | −$299.8M |
| Net margin | 1773.6% | -3400.9% | -1528.9% | -3200.2% | 13294.2% | -592.0% | -3629.2% |
| EPS (diluted) | 1.75 | -1.18 | -1.26 | -1.42 | 5.23 | -0.24 | -0.43 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $82M | $-1.25 | $-3.67–$-0.21 | 4 |
| 2028 | $605M | $-0.98 | $-2.87–$-0.17 | 4 |
| 2029 | $1.8B | $0.17 | $-5.57–$6.31 | 7 |
| 2030 | $3.2B | $1.22 | $0.21–$3.57 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.90
Price
$35.70
Implied downside
-92%
Peer comparison
Roivant Sciences Ltd. Common Shares
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
www.roivant.com- Employees
- 721
- IPO / List date
- Oct 1, 2021
- HQ
- LONDON
Held by traders on TradeandTell
No one on the platform currently holds ROIV.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ROIV as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ROIV yet.
